NCT05820906View on ClinicalTrials.gov

Cadonilimab Plus Regorafenib and Gem-Cis Chemotherapy in Advanced Biliary Tract Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

September 1, 2024

Study Completion Date

September 1, 2025

Conditions
Advanced Biliary Tract Cancer
Interventions
DRUG

Cadonilimab+Regorafenib+GC

Cadonilimab:10mg/kg, iv,q3w,D1 Regorafenib: 80mg, po, orally once daily Gemcitabine:1000 mg/m2, iv, Q3W，D1,D8 Cisplatin:25 mg/m2, iv, Q3W, D1,D8

Trial Locations (1)

300308

RECRUITING

Tianjin Cancer Hospital Airport Hospital, Tianjin

All Listed Sponsors
lead

Tianjin Medical University Cancer Institute and Hospital

OTHER